- Home
- CARA
as 12-18-2024 2:33pm EST
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | STAMFORD |
| Market Cap: | 16.7M | IPO Year: | 2014 |
| Target Price: | $1.00 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.23 - $1.15 | Next Earning Date: | 11-14-2024 |
| Revenue: | $8,686,000 | Revenue Growth: | -59.08% |
| Revenue Growth (this year): | -67.77% | Revenue Growth (next year): | -3.00% |
Stock Insider Trading Activity of Cara Therapeutics Inc. (CARA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Posner Christopher | CARA | PRESIDENT AND CEO | Nov 4 '24 | Sell | $0.29 | 3,668 | $1,063.72 | 168,768 |
Latest Cara Therapeutics Inc. News
CARA Breaking Stock News: Dive into CARA Ticker-Specific Updates for Smart Investing
MT Newswires
10 hours ago
Cara Therapeutics Agrees to Merge With Tvardi Therapeutics
GlobeNewswire
10 hours ago
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
Simply Wall St.
a month ago
Cara Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Associated Press Finance
a month ago
Cara: Q3 Earnings Snapshot
Associated Press Finance
4 months ago
Cara: Q2 Earnings Snapshot
MT Newswires
5 months ago
Cara Therapeutics Explores Strategic Alternatives; Shares Rise Pre-Bell
GlobeNewswire
5 months ago
Cara Therapeutics Announces Exploration of Strategic Alternatives
MT Newswires
6 months ago
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday
Compare CARA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CARA Cara Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.